Bevacizumab and Tamoxifen are valid therapeutic options for metastatic breast cancer (mBC) patients. In this report, we describe a 47 year old woman with mBC successfully treated with a maintenance therapy with Bevacizumab+Tamoxifen. A maintenance approach using 2 different drugs with different targets and mechanism of action, such as anti-angiogenic and anti-hormonal treatment is particularly intriguing because they affect different pathways involved in mBC progression. Further studies including a large number of patients are needed, in order to select women who could benefit from this maintenance approach.

Roviello, G., Francini, E., Perrella, A., Laera, L., Mazzei, M.A., Guerrini, S., et al. (2015). Five years of stable disease with maintenance therapy using bevacizumab and tamoxifen in a patient with metastatic breast cancer. CANCER BIOLOGY & THERAPY, 16(4), 493-497 [10.1080/15384047.2015.1017692].

Five years of stable disease with maintenance therapy using bevacizumab and tamoxifen in a patient with metastatic breast cancer

ROVIELLO, GIANDOMENICO;PERRELLA, ARMANDO;LAERA, LETIZIA;MAZZEI, MARIA ANTONIETTA;GUERRINI, SUSANNA;ROVIELLO, FRANCO;MARRELLI, DANIELE;PETRIOLI, ROBERTO
2015-01-01

Abstract

Bevacizumab and Tamoxifen are valid therapeutic options for metastatic breast cancer (mBC) patients. In this report, we describe a 47 year old woman with mBC successfully treated with a maintenance therapy with Bevacizumab+Tamoxifen. A maintenance approach using 2 different drugs with different targets and mechanism of action, such as anti-angiogenic and anti-hormonal treatment is particularly intriguing because they affect different pathways involved in mBC progression. Further studies including a large number of patients are needed, in order to select women who could benefit from this maintenance approach.
2015
Roviello, G., Francini, E., Perrella, A., Laera, L., Mazzei, M.A., Guerrini, S., et al. (2015). Five years of stable disease with maintenance therapy using bevacizumab and tamoxifen in a patient with metastatic breast cancer. CANCER BIOLOGY & THERAPY, 16(4), 493-497 [10.1080/15384047.2015.1017692].
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11365/984174
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo